TREATMENT OF PULMONARY AND PLEURAL FIBROSIS USING HSP27 INHIBITORS

摘要

Reduction of HSP27 expression is in beneficial in the treatment of pleural and pulmonary fibrosis and in particular subpleural fibrosis and IPF. Pharmaceutical compositions for this purpose contain an inhibitor of HSP27 and a pharmaceutically acceptable carrier.